Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2424-2431

  Lai, Ming Tain ^a   Munshi, Vandna ^a   Touch, Sinoeun ^a   Tynebor, Robert M ^a   Tucker, Thomas J ^a   McKenna, Philip M ^a   Williams, Theresa M ^a   DiStefano, Daniel J ^a   Hazuda, Daria J ^a   Miller, Michael D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETHER DERIVATIVE; ETRAVIRINE; INDAZOLE DERIVATIVE; LAMIVUDINE; MARAVIROC; MK 4965; NEVIRAPINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RALTEGRAVIR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; FETAL BOVINE SERUM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; SERUM; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

ANTI-HIV AGENTS; BENZOXAZINES; CELL LINE; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; NEVIRAPINE; PYRAZOLES; PYRIDAZINES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 67049145601     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01559-08     Document Type: Article

References (35)

1. Ambrose, Z., J. G. Julias, P. L. Boyer, V. N. Kewalramani, and S. H. Hughes. 2006. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80:2578-2581. (Pubitemid 43271563)
2. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M. P. de Bethune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008. (Pubitemid 32448520)
4. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
5. Boffito, M., A. Winston, A. Jackson, C. Fletcher, A. Pozniak, M. Nelson, G. Moyle, I. Tolowinska, R. Hoetelmans, D. Miralles, and B. Gazzard. 2007. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 21:1449-1455. (Pubitemid 46988005)
6. Carr, J. K., M. O. Salminen, J. Albert, E. Sanders-Buell, D. Gotte, D. L. Birx, and F. E. McCutchan. 1998. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 247:22-31. (Pubitemid 28384022)
7. Castro, H. C., N. I. V. Loureiro, M. Pujol-Luz, A. M. T. Souza, M. G. Albuquerque, D. O. Santos, L. M. Cabral, I. C. Frugulhetti, and C. R. Rodrigues. 2006. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr. Med. Chem. 13:313-324.
8. Chou, T. 1974. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol. Pharmacol. 10:235-247.
9. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
10. Clark, S. A., N. S. Shulman, R. J. Bosch, and J. W. Mellors. 2006. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 20:981-984.
11. Das, K., P. J. Lewi, S. H. Hughes, and E. Arnold. 2005. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88:209-231.
12. Delaugerre, C., R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, J. M. Huraux, C. Katlama, and V. Calvez. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 65:445-448.
13. DiCenzo, R., D. Peterson, M. Cruttenden, G. Morse, G. Riggs, H. Gelbard, and G. Schifitto. 2004. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4328-4331.
14. Geretti, A. M. 2008. Shifting paradigms: the resistance profile of etravirine. J. Antimicrob. Chemother. 62:643-647.
15. Gotte, M., X. G. Li, and M. A. Wainberg. 1999. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys. 365:199-210.
16. Harris, M. E., S. Maayan, B. Kim, M. Zeira, G. Ferrari, D. L. Birx, and F. E. McCutchan. 2003. A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. AIDS Res. Hum. Retrovir. 19:1125-1133.
17. Hopkins, A. L., J. S. Ren, R. M. Esnouf, B. E. Willcox, E. Y. Jones, C. Ross, T. Miyasaka, R. T. Walker, H. Tanaka, D. K. Stammers, and D. I. Stuart. 1996. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1589-1600.
18. Huang, W., T. Wrin, and A. V. Gamarnik. 2002. RT mutations that confer NNRTI resistance may also impair replication capacity. Antivir. Ther. 7:S79.
19. Jackson, J. B., S. Barnett, E. Piwowar-Manning, L. Apuzzo, C. Raines, C. Hendrix, F. Hamzeh, and J. Gallant. 2003. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 17:547-553. (Pubitemid 36293108)
20. Kaltenbach, J. P., M. H. Kaltenbach, and W. B. Lyons. 1958. Nigrosin as a dye for differentiating live and dead ascites cells. Exp. Cell Res. 15:112-117.
21. Lazzarin, A., T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48. (Pubitemid 47017467)
22. Llibre, J. M., J. R. Santos, T. Puig, J. Molto, L. Ruiz, R. Paredes, and B. Clotet. 2008. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J. Antimicrob. Chemother. 62:909-913.
23. Madruga, J. V., P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38. (Pubitemid 47017466)
24. Moore, J. P., and M. Stevenson. 2000. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 1:40-49.
25. Munshi, V., M. Lu, P. Felock, R. J. Barnard, D. J. Hazuda, M. D. Miller, and M. T. Lai. 2008. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence- based reverse transcriptase polymerase assay. Anal. Biochem. 374:121-132.
26. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
27. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
28. Shaw-Reid, C. A., V. Munshi, P. Graham, A. Wolfe, M. Witmer, R. Danzeisen, D. B. Olsen, S. S. Carroll, M. Embrey, J. S. Wai, M. D. Miller, J. L. Cole, and D. J. Hazuda. 2003. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278:2777-2780.
29. Shulman, N. S., R. J. Bosch, J. W. Mellors, M. A. Albrecht, and D. A. Katzenstein. 2004. Genetic correlates of efavirenz hypersusceptibility. AIDS 18:1781-1785. (Pubitemid 39179629)
30. Soriano, V., and C. de Mendoza. 2002. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials 3:237-248. (Pubitemid 34704872)
31. Spira, S., M. A. Wainberg, H. Loemba, D. Turner, and B. G. Brenner. 2003. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J. Antimicrob. Chemother. 51:229-240.
32. Sweeney, Z. K., and K. Klumpp. 2008. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr. Opin. Drug Discov. Dev. 11:458-470.
33. Tachedjian, G., and A. Mijch. 2004. Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors. Sex. Health 1:81-89.
34. Tucker, T. J., J. T. Sisko, R. M. Tynebor, T. M. Williams, P. J. Felock, J. A. Flynn, M.-T. Lai, Y. Liang, G. McGaughey, M. Liu, M. D. Miller, G. Moyer, V. Munshi, R. Perlow-Poehnelt, S. Prasad, J. C. Reid, R. Sanchez, M. Torrent, J. P. Vacca, B. Wan, and Y. Yan. 2008. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3, 4-b]pyridine-3-yl)methoxy]-2chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J. Med. Chem. 51:6503-6511.
35. Vingerhoets, J., H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M. P. de Bethune. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782. (Pubitemid 41433197)